15-min delayed · Jul 28, 3:45 PM ET · Get real-time quotes →
The Quantellect read.Of the 2 firms covering Inovio Pharmaceuticals Inc, 1 rate it Buy or better, 1 sit at Hold, and 0 rate it Sell or worse, a moderate buy consensus. Targets range widely, $2.50 to $6.00 (about 2.4x), a sign of real disagreement on valuation. The average target of $4.25 sits 317% above the current $1.02. The rating mix has stayed broadly stable, with Buy-side ratings easing from 2 to 1 over recent months. On the fundamentals, the Street sees consensus EPS building from about $-0.24 next quarter toward $-0.60 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS2 ratings
Moderate Buy
Strong Buy00%
Buy150%
Hold150%
Sell00%
Strong Sell00%
Based on 2 analysts giving stock ratings to Inovio Pharmaceuticals Inc.
As of Jul, 1 of 2 firms rate INO a Buy (1 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
INO EPS & revenue forecast
EPS · NEXT QUARTER
$-0.24
Range $-0.25 – $-0.24 · 2 analysts · -72% YoY
Next period, 2 analysts expect Inovio Pharmaceuticals Inc to earn $-0.24 a share (range $-0.25 – $-0.24), versus $-0.87 a year earlier. Full-year consensus is $-1.14, growing to $-0.60 the year after.
REVENUE · NEXT QUARTER
$0
Range $0 – $0 · 2 analysts
Revenue is expected to reach $0 (range $0 – $0). Full-year consensus is $666.7K, rising to $51.3M next year.
Top analysts covering Inovio Pharmaceuticals Inc
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on INO.
#1
Roy Buchanan
JMP Securities · Rank #109
Buy
$12.00+1076.5% to target
Overall win rate
48%
+ Follow
#2
Gregory Renza
RBC Capital · Rank #179
Hold
$5.00+390.2% to target
Overall win rate
34%
+ Follow
#3
Raghuram Selvaraju
HC Wainwright & Co. · Rank #249
Hold
$2.50+145.1% to target
Overall win rate
37%
+ Follow
#4
Edward Tenthoff
Piper Sandler · Rank #277
Buy
$6.00+488.2% to target
Overall win rate
29%
+ Follow
#5
Jay Olson
Oppenheimer · Rank #302
Buy
$13.00+1174.5% to target
Overall win rate
32%
+ Follow
INO stock forecast FAQ
What is INO's average 12-month price target?+
The 2 analysts with a live target average $4.25 for Inovio Pharmaceuticals Inc over the next 12 months, ranging from a $6.00 high to a $2.50 low.
Is INO stock a Buy, Sell or Hold right now?+
The current consensus is Moderate Buy. Of the 2 analyst ratings, 1 are Buy or Strong Buy, 1 are Hold, and 0 are Sell or Strong Sell.
What are the highest and lowest price targets for INO?+
The Street-high target is $6.00 (Piper Sandler), and the Street-low is $2.50 (HC Wainwright & Co.). The average of all 2 active targets is $4.25.
How many Wall Street analysts cover INO?+
2 analysts have an active rating on Inovio Pharmaceuticals Inc, and 2 firms carry a live 12-month price target.
Who is the most accurate analyst covering INO?+
Among analysts who currently cover INO, Roy Buchanan of JMP Securities has the strongest overall Quantellect track record (Rank #109). Their current call is Buy with a $12.00 target.
What is Inovio Pharmaceuticals Inc's projected EPS for next quarter?+
The consensus estimate is $-0.24 per share (range $-0.25 – $-0.24) across 2 analysts. Full-year EPS is projected at $-1.14, rising to $-0.60 the following year.
How much revenue is Inovio Pharmaceuticals Inc expected to report next quarter?+
Consensus revenue is $0 (range $0 – $0). Full-year revenue is projected at $666.7K, growing to $51.3M next year.
Have analysts been upgrading or downgrading INO lately?+
As of Jul, 1 of 2 firms rate INO a Buy (1 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their INO calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.
